The United States Food and Drug Administration (US FDA) has completed the inspection at Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma’s Unit-VII, an API manufacturing facility, situated at Parwada Mandal, Anakapally District, Andhra Pradesh from May 5 to May 10, 2024. The inspection closed with 1 observation. The observation is of procedural in nature and will be responded to within the stipulated time.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
